Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beigene Ltd ADR
(NQ:
BGNE
)
193.82
-1.81 (-0.93%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors
April 11, 2023
This month, Enlivex Therapeutics Ltd.
Via
Benzinga
Why BeiGene Stock Jumped Thursday
April 06, 2023
A collaboration deal helped send the Chinese biotech stock higher.
Via
The Motley Fool
Beigene Ltd. (NASDAQ: BGNE) Highlighted for Surprising Price Action
April 06, 2023
Via
Investor Brand Network
BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity
March 30, 2023
From
BeiGene
Via
Business Wire
BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey
March 21, 2023
From
BeiGene
Via
Business Wire
BeiGene Earnings Perspective: Return On Capital Employed
March 02, 2023
Via
Benzinga
4 Analysts Have This to Say About BeiGene
January 20, 2023
Via
Benzinga
FDA Approves BeiGene's Brukinsa For Chronic Lymphocytic Leukemia
January 20, 2023
Via
Benzinga
Silicon Valley Bank Collapse Might Have Limited Impact On Asia, But Confidence Seems Shaken
March 13, 2023
Some Asian firms have disclosed cash deposits at troubled U.S. lender Silicon Valley Bank (NASDAQ: SIVB), known for its deep ties with the healthcare and tech sector. Most emphasized that the amounts...
Via
Benzinga
BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results
February 27, 2023
From
BeiGene, Ltd.
Via
Business Wire
Nasdaq, S&P 500 Futures Rebound In New Trading Week But Rising Bond Yields Remain A Risk
February 27, 2023
US stocks are coming off a lackluster week and early indications suggest a reversal in sentiment in the new trading week. While rising bond yields could be a cause of concern, the recent weakness could...
Via
Benzinga
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
February 25, 2023
Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between...
Via
Talk Markets
Zymeworks Cancer Candidate Shows Objective Response Of 41% In Bile Duct Cancer
December 19, 2022
Via
Benzinga
BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
February 24, 2023
From
BeiGene
Via
Business Wire
BeiGene to Present at Cowen’s 43rd Annual Healthcare Conference
February 24, 2023
From
BeiGene
Via
Business Wire
Five Best And Worst Performing Healthcare Stocks In January 2023
February 05, 2023
After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022. As well, 2023 is expected to be another promising year for the sector. Let’s take a look at the five best and...
Via
Talk Markets
New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care
February 03, 2023
From
BeiGene
Via
Business Wire
BeiGene to Present at Upcoming Investor Conferences
February 01, 2023
From
BeiGene
Via
Business Wire
Is Johnson & Johnson Still a Good Dividend Stock to Buy?
January 26, 2023
A disappointing fourth-quarter performance has some investors worried about the giant healthcare conglomerate's outlook.
Via
The Motley Fool
Five Best And Worst Performing Healthcare Stocks In December 2022
January 22, 2023
Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst...
Via
Talk Markets
Draganfly To Rally Around 87%? Here Are 10 Other Analyst Forecasts For Friday
January 20, 2023
SVB Leerink raised the price target for BeiGene, Ltd. (NASDAQ: BGNE) from $236 to $300. SVB Leerink analyst Andrew Berens maintained an Outperform rating. BeiGene shares rose 2% to $279.90 in...
Via
Benzinga
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
January 19, 2023
From
BeiGene
Via
Business Wire
BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA
January 19, 2023
From
BeiGene
Via
Business Wire
BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List
January 18, 2023
From
BeiGene
Via
Business Wire
BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium
January 17, 2023
From
BeiGene
Via
Business Wire
These Were The Five Best And Worst Performing Large-Cap Stocks In Q4 2022
January 06, 2023
The year 2022 proved to be the worst calendar year for the S&P 500 since 2008. The benchmark index dropped more than 5% in December and almost 20% for the full year. Let’s take a look at the five best...
Via
Talk Markets
BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference
January 04, 2023
From
BeiGene
Via
Business Wire
BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab
December 30, 2022
From
BeiGene
Via
Business Wire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
December 27, 2022
Biopharma stocks were not immune to the broader market downturn seen for much of 2022.
Via
Benzinga
Week In Review: Boston Scientific Pays $523 Million For Majority Stake In Beijing Acotec Scientific
December 17, 2022
Boston Scientific will pay $523 million for a 65% stake in Acotec Scientific, a Beijing medical device company. Boston Scientific said the acquisition will build up its presence in China, and it will...
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.